This study introduced a progressive approach to address the challenges associated with drug delivery in hepatitis B by developing a 3D printed subcutaneous implant. The implant, composed of a polymer-reinforced bovine serum albumin hydrogel crosslinked with glutaraldehyde, exhibited shear thinning and thixotropic behavior. This allows it to undergo transformation into an implant using a semisolid extrusion-based 3D printing technique. Thorough analysis encompassing physical, thermal, and FTIR assessments ensured thermal and chemical stability of the implant. Scanning electron microscopy revealed the highly porous microstructures of the hydrogel implant, enhancing its suitability for drug encapsulation. Swelling study showed only 7.88 % swelling of the implant after 28 days, suggesting restricted water movement into the implant matrix, leading to a gradual release of the encapsulated drug. The biodegradable nature of the implant was confirmed using an enzyme degradation study. Notably, the hydrogel implant exhibited sustained release of tenofovir of approximately 63 % over a 28-day period, presenting a promising avenue for prolonged therapeutic interventions in both hepatitis B. Furthermore, the crosslinked hydrogel was found to be cytocompatible in human kidney and dermal fibroblast cells. Overall, this work signifies a notable advancement in implantable drug delivery systems utilizing both hydrogel and the emerging 3D printing technique, offering a potential solution for the sustained and localized treatment of chronic viral infections.